We compared prostate-specific antigen (PSA) assay systems [i.e., free PSA (f-PSA) and the corresponding total PSA (t-PSA) assay] from four different manufacturers as well as the f-PSA/t-PSA ratios with regard to their ability to discriminate between benign prostate hyperplasia (BPH) and prostate cancer (PCA). ROC analysis showed similar areas under the curves (AUCs) with different assay systems. For the entire patient population the AUCs of the f-PSA/t-PSA ratio were not or slightly increased compared with the sole measurement of t-PSA (t-PSA, 0.792-0.820; f-PSA/t-PSA ratio, 0.685-0.859). In contrast, for only those patients who showed t-PSA concentrations within the diagnostic gray area of 4 -25 g/L t-PSA, the AUCs were greater for the f-PSA/ t-PSA ratio than for measurement of t-PSA alone (t-PSA, 0.608 -0.647; f-PSA/t-PSA ratio, 0.690 -0.806). These results were confirmed by the predictive values of the negative results (NPVs) of the t-PSA assays and the f-PSA/t-PSA ratios (assay thresholds corresponding to a 95% detection limit). Compared with the sole t-PSA measurement there was no mentionable increase in the NPVs due to the f-PSA/t-PSA ratio for the entire patient population, but an increase up to 49% when limited to t-PSA concentrations within 4 -25 g/L. We therefore conclude that the f-PSA/t-PSA ratio may be helpful for differential diagnosis of BPH and PCA within the diagnostic gray area of 4 -25 g/L t-PSA.
Prostate-specific antigen (PSA) 1 is a serine protease with a chymotrypsin-like activity [1, 2] . The 33-kDa single-chain glycoprotein is produced by the secretory epithelium of the prostate [3] . PSA is released from the normal prostate and appears at low serum concentrations in healthy men. Studies with reverse transcription-PCR have shown that PSA also is expressed at a low concentration in peripheral blood cells and other tissues [4] . High serum concentrations can be detected in patients with advanced prostate cancer (PCA) [5] . Therefore PSA is applied as a tumor marker for the clinical management of PCA [6] . However, increased PSA concentrations in serum also occur in patients with benign prostate hyperplasia (BPH) [7] . Hence the goal is to discriminate clearly between BPH and PCA in the clinical laboratory to spare the patient invasive diagnostic procedures, such as a prostate biopsy.
In human serum PSA occurs in two forms: free PSA (f-PSA) and complexed PSA. The major form is a complex of PSA and ␣ 1 -antichymotrypsin (ACT). The fraction of f-PSA was shown to be substantially smaller in patients with untreated PCA than in patients with BPH. Therefore combined measurements of f-PSA and total PSA (t-PSA) may lead to a better discrimination between BPH and PCA [8] [9] [10] . Some recent studies have already shown that the f-PSA/t-PSA ratio is helpful in the differential diagnosis of BPH and PCA [11, 12] .
In this study we investigated assay systems (i.e., f-PSA and the corresponding t-PSA assay) from four different manufacturers. Our aim was to compare these assays with regard to their differences in discriminating between BPH and PCA as well as to show the diagnostic value of the f-PSA/t-PSA ratio.
Materials and Methods
Assays. Assay systems performed were Enzymun-Test PSA/Enzymun-Test PSAf (Boehringer Mannheim), Cispack PSA 2-US/FPSA-RIACT (Cis, Bagnols/Cèze, France), Immulite PSA/Immulite Free PSA [Diagnostic Products Corp. (DPC)], and Tandem-E PSA/Tandem-R free PSA (Hybritech). Additionally, in the calibrator PSA-ACT was assessed by the PSA-ACT assay (Cell Diagnostica, Mü nster, Germany). With the exception of the Cis and Hybritech f-PSA assays and the PSA-ACT assay, which were performed manually, the measurements were performed automatically on Boehringer ES 600, Cispack 4200, DPC Immulite, or Hybritech Photon Era, respectively. All measurements were performed in duplicate. Controls were measured in each assay run. Assay characteristics are shown in Table 1 .
Patients. Sera from 80 patients were investigated: 30 patients with BPH, ages 47-80 years, prostate volume 26 -105 cm 3 , determined by transrectal ultrasound with a method described by Semjonow et al. [13] ; 50 patients with PCA, ages 40 -88 years, stages T1 (n ϭ 3), T2 (n ϭ 7), T3 (n ϭ 35), T4 (n ϭ 5), N0-2, M0-1, G1-3. In all cases diagnosis was confirmed histologically. All patients were untreated until blood collection.
Blood samples. Blood was collected by venipuncture into a 10-mL Sarstedt serum monovette before rectal examination. Serum was obtained by centrifugation at 400g for 15 min and immediately frozen at Ϫ70°C.
Calibrator. The application of PSA measurements for clinical monitoring of PCA leads to misinterpretations because of differences of the commercially available PSA assays. To highlight this matter, we used reference material (PSA-Bioref-17; Bioref, Mö mbris, Germany) with four different concentrations of t-PSA (referred to below as ultralow, low, mid, and high preparation) as an assayindependent control material.
Statistical analysis. Linear regression and Pearson correlation analyses were performed to compare PSA measurement by different assays. For the entire patient population as well as for only those patients who showed t-PSA concentrations within the range of 4 -25 g/L, ROC analysis [including calculation of the area under the curve (AUC) and 95% confidence limits] was performed with the MedCalc software package (MedCalc Software, Mariakerke, Belgium). AUCs were compared for the entire patient population. When P Ͻ0.05, differences of the AUCs were defined as significant. The predictive values of the negative results (NPV) of the t-PSA assays and the f-PSA/t-PSA ratios were calculated at the assay thresholds corresponding to a 95% detection limit. The difference between the NPV of the f-PSA/t-PSA ratio and the sole measurement of t-PSA represents the number of possibly eliminated prostate biopsies because of the f-PSA/t-PSA ratio. Confidence intervals of NPVs were estimated by SAS Makro cibinom for exact confidence limits for binomial proportion (SAS Institute). 
13 
Results
Calibrator. The t-PSA and f-PSA results varied among assays, with higher differences at higher PSA concentrations. Because the concentration of PSA-ACT was not specified by the manufacturer of the calibrators, we determined it and found it to be 0.0 -0.5 g/L (Table 2) .
Assay comparisons.
Comparing the results of the Tandem-E PSA assay (x) with the results of the other t-PSA assays (y) gave slopes that varied from 0.79 to 1.10 (intercept 0.01-2.37 g/L). With the results of the Tandem-R free PSA assay (x) vs the results of the other f-PSA assays (y), the slopes were from 0.62 to 1.09 (intercept 0.11-0.75 g/L) (Fig. 1) . 
Diagnostic performance of t-PSA and f-PSA measurements and the f-PSA/t-PSA ratio.
For ROCs, AUCs of the t-PSA assays varied between 0.792 (Cispack PSA 2-US) and 0.833 (Immulite PSA). For f-PSA measurements the areas were from 0.634 (Immulite Free PSA) to 0.692 (Enzymun-Test PSAf), for the f-PSA/t-PSA ratio from 0.685 (Boehringer) to 0.859 (DPC) (Fig. 3, Table 3 ). With regard to the differences in PSA measurement by different assays, the frequently discussed diagnostic gray area between 4 and 10 g/L for the differential diagnosis between BPH and PCA was extended to 4 -25 g/L t-PSA in our study. Limited to patients with t-PSA values of 4 -25 g/L, the AUCs obtained from ROC analysis for the t-PSA measurement were low and varied from a minimum of 0.608 (Enzymun-Test PSA) to a maximum of 0.647 (Immulite PSA). The corresponding areas of the f-PSA/t-PSA ratios were higher for all assay systems and varied from 0.690 (Boehringer) to 0.806 (Hybritech).
For the entire patient population differences between the assays' AUCs were not significant except for the differences between the Hybritech and DPC t-PSA measurement and the Hybritech and DPC f-PSA/t-PSA ratios (in both cases P Ͻ0.05) ( Table 3) .
The overall diagnostic performance of an assay may be well described by the AUC, but for the clinical use of tumor markers, the NPVs at a given detection limit are more important. Within the entire t-PSA range the NPVs at a 95% detection limit were similar for all t-PSA assays: from 0.78 (Tandem-E PSA) to 0.82 (Cispack PSA 2-US). For the f-PSA/t-PSA ratio the NPVs varied from 0.75 (DPC and Hybritech) to 0.83 (Cis). Compared with the sole measurement of t-PSA, there was no mentionable increase in the percentage of possibly eliminated prostate biopsies by calculating the f-PSA/t-PSA ratio. For patients with t-PSA concentrations of 4 -25 g/L the NPVs at a 95% detection limit ranged from a minimum of 0.18 (Enzymun-Test PSA) to a maximum of 0.76 (Tandem-E PSA). In the calculation of the f-PSA/t-PSA ratio the NPVs varied from 0.62 (Boehringer, DPC) to 0.85 (Hybritech). Within this range the number of possibly eliminated prostate biopsies as a result of the f-PSA/t-PSA ratio compared with the sole t-PSA measurement varied from 9% (Hybritech) to 49% (Cis) ( Table 4) .
Discussion
The application of PSA measurements for clinical monitoring of PCA leads to misinterpretations because of differences among commercially available PSA assays. Similarly, PSA results of calibrators varied among assays; in our study, we applied calibrators containing virtually only f-PSA. The portion of PSA-ACT was Ͻ0.5 g/L in all calibrator preparations, as determined with the PSA-ACT assay. For the Cis and DPC systems the measurement with the t-PSA assay led to higher values than with the corresponding f-PSA assay. In contrast, the results of t-PSA and f-PSA measurement in the calibrators with the Boehringer and Hybritech assays led to similar results for both t-PSA and f-PSA (Table 2) . A possible source of these discrepancies might be the overestimation of f-PSA by some t-PSA assays. At this point the absence of PSA-ACT is a limitation for the use of this calibrator as a control for PSA measurements. Because in patients' serum the major form of PSA is the PSA-ACT complex, a calibrator with a defined portion of PSA-ACT is required. However, as shown by Chen et al. [14] , the use of material containing defined portions of PSA-ACT and f-PSA as calibrators resulted in good agreement between different assays for just this f-PSA/t-PSA ratio. The results of the method comparison confirm the finding of differences in PSA measurement by different assays. Although the correlation coefficient exceeded 0.92 in all assay comparisons (Hybritech t-PSA and f-PSA vs all other assays), there were remarkable differences in slopes and intercepts (Fig.  1) . Additionally the detection limits of the t-PSA assays for f-PSA differed considerably as demonstrated by the slopes of the regression curves of the corresponding f-PSA and t-PSA assays (Fig. 2) .
A major aim of PSA determination is to investigate the necessity of a prostate biopsy. However, this is not always easy, because in the case of BPH, t-PSA can reach high concentrations, whereas in the case of PCA sometimes low values are measured. In our investigation we compared the diagnostic value of the t-PSA assays and the f-PSA/t-PSA ratio by ROC analysis and by calculating differences of the NPVs at a detection limit of 95%.
Within the entire t-PSA range the AUCs were similar for the four t-PSA assays. A slight increase of the AUC was found for the f-PSA/t-PSA ratio only with the Cis and DPC systems. The increase of the NPVs for the f-PSA/t-PSA ratio was not remarkable when the entire t-PSA range was used. Compared with the sole measure- Fig. 3 . ROC analysis of f-PSA and t-PSA measurement and the f-PSA/t-PSA ratio. ment of t-PSA, the f-PSA/t-PSA ratio allowed the potential elimination of prostate biopsies in up to 3% more cases.
With regard to the differences in PSA measurement by different assays, the frequently discussed diagnostic gray area between 4 and 10 g/L was extended up to 4 -25 g/L t-PSA in our study. For patients with t-PSA concentrations of 4 -25 g/L, AUCs were smaller than within the entire range, indicating the poor discriminating power of t-PSA between BPH and PCA. However, in all assay systems the AUCs increased for the f-PSA/t-PSA ratio. Moreover, compared with the sole measurement of t-PSA, the prostate biopsy would possibly be eliminated in up to 49% more cases because of the f-PSA/t-PSA ratio (Table  4) . That within the 4 -25 g/L t-PSA range the Hybritech system showed an increase of only 9% may be a result of the already high NPV of the Hybritech t-PSA assay. We therefore suggest that a lack of specificity for patients showing t-PSA concentrations within the diagnostic gray area of 4 -25 g/L can be overcome by calculating the f-PSA/t-PSA ratio.
The decreasing or the poor increasing, respectively, of the AUCs of the f-PSA/t-PSA ratio when applied to the entire spectrum of t-PSA values can be attributed to low sensitivities of the ratio at low and high concentrations of t-PSA. In early cancer stages and at low concentrations of t-PSA, PSA measurement is influenced mainly by immunological cross-reactions and by PSA of nonprostatic origin (e.g., perirectal and periurethral glands, blood cells) [6] . On the other hand, ACT is produced by the tumor itself, and therefore the production of PSA and ACT depends not only on the tumor size, but also on the grading of the tumor [15] . With higher grading, tumor cells presumably lose their ability to produce ACT, and 
